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Chimeric genes can be caused by structural genomic rearrangements that fuse together portions of two different genes to create a novel
gene. We hypothesize that brain-expressed chimeras may contribute to schizophrenia. Individuals with schizophrenia and control in-
dividuals were screened genome wide for copy-number variants (CNVs) that disrupted two genes on the same DNA strand. Candidate
events were filtered for predicted brain expression and for frequency < 0.001 in an independent series of 20,000 controls. Four of
124 affected individuals and zero of 290 control individuals harbored such events (p ¼ 0.002); a 47 kb duplication disrupted MATK
and ZFR2, a 58 kb duplication disrupted PLEKHD1 and SLC39A9, a 121 kb duplication disrupted DNAJA2 and NETO2, and a
150 kb deletion disrupted MAP3K3 and DDX42. Each fusion produced a stable protein when exogenously expressed in cultured cells.
We examined whether these chimeras differed from their parent genes in localization, regulation, or function. Subcellular localizations
of DNAJA2-NETO2 and MAP3K3-DDX42 differed from their parent genes. On the basis of the expression profile of the MATK pro-
moter, MATK-ZFR2 is likely to be far more highly expressed in the brain during development than the ZFR2 parent gene. MATK-
ZFR2 includes a ZFR2-derived isoform that we demonstrate localizes preferentially to neuronal dendritic branch sites. These results
suggest that the formation of chimeric genes is a mechanism by which CNVs contribute to schizophrenia and that, by interfering
with parent gene function, chimeras may disrupt critical brain processes, including neurogenesis, neuronal differentiation, and den-
dritic arborization.Introduction
Structural rearrangements arise continuously in the
human genome. Although many are benign, a subset
contributes to disease, particularly neurodevelopmental
illnesses such as schizophrenia (MIM 181500).1–4 The
mechanisms by which rare structural variants lead to
disease are as heterogeneous as the mutations themselves
and likely include gene dosage effects (both overexpres-
sion5 and haploinsufficiency6), unmasking of recessive
alleles by a deletion on one chromosome,7 and epistatic
interactions between multiple events.8 In addition,
some rearrangements result in the formation of chimeric
genes. Gene fusions are uniquely suited to play crucial
roles in both evolution and disease because they can
differ from parent genes in localization, regulation,
and/or function.9 Adaptive chimeric genes have been
incorporated into genomes across many phyla, includ-
ing a handful identified in the hominid lineage.10,11
However, the majority of chimeras arising de novo in
the genome are likely detrimental,12 as is the case when
oncogenic fusions such as BCR-ABL (MIM 151410)13 arise
somatically.
Less is known about the role of germline chimeras in
human disease. Two prior reports of chimeric genes in
individuals with schizophrenia suggest that chimerism
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The Americreported a rare deletion in an individual with juvenile
onset schizophrenia that resulted in a chimera of SKP2-
SLC1A3 (MIM 601436 and 600111). This chimeric gene
was predicted to alter the expression and function of
SLC1A3, which codes for GLAST, a glial glutamate trans-
porter known to regulate neurotransmitter concentration
at excitatory synapses.1 In addition, the well-documented
t(1;11) translocation which segregates closely with psychi-
atric illness, including schizophrenia, in a large Scottish
kindred disrupts DISC1 (MIM 605210) on chromosome 1
and the noncoding RNA DISC1FP1 (also called Boymaw)
on chromosome 11.4 Chimeric transcripts fusing these
two genes are present in carrier lymphoblasts,14 and
a recent study demonstrated that the resulting fusion
proteins have altered localization and lead to severe
mitochondrial dysfunction.15 A systematic survey of
copy-number variation in persons with autism (MIM
209850) revealed potential candidate chimeric events but
no difference in frequency between affected and control
individuals.16
In this study, we seek to systematically characterize the
role of chimeric genes in schizophrenia by identifying
rare, germline chimeras in individuals with schizophrenia
and control individuals. We hypothesize that brain-
expressed chimeric genes in these individuals contribute
to schizophrenia by disrupting critical neuronal pathways
involving the parent genes.ton, Seattle, WA 98195, USA; 2Department of Psychiatry and Behavioral
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Subjects and Methods
Subjects
Our case series comprised 124 individuals with schizophrenia or
schizoaffective disorder whose diagnostic status was confirmed
by diagnostic interview with the Structured Clinical Interview
for DSM-IV disorders (SCID) for adults or the KID-SCID for
youths. The average age of onset of schizophrenia was 19 years
(SD ¼ 5.0 years, range ¼ 9–35 years). When possible, we enrolled
family members of affected individuals, but, for most affected
individuals, family member contact was not possible because of
institutionalization. DNA was extracted from whole blood for
array comparative genomic hybridization (aCGH), and lympho-
blastoid cell lines were also generated in our lab for each individ-
ual. These cell lines were used for RNA and protein analyses. The
control group comprised 122 individuals without mental illness
from National Institute of Mental Health Genomics Research
and Repository Distribution 5 and 168 individuals without mental
illness who agreed that their DNA may be used as controls for
projects in our laboratory. All control individuals were unrelated
to each other, older than 35 years, and matched to affected
individuals by self-identified race. The project was approved by
the appropriate University of Washington and Washington state
ethics committees, and informed consent was obtained for every
participant.
Detection of Copy-Number Variants
DNA from all 124 individuals with schizophrenia and 122 of
the control individuals was hybridized to NimbleGen HD2 micro-
array slides (average probe density ¼ 1 probe per kb) against a
well-characterized reference subject (SKN1). aCGH data were
normalized, and copy-number variants (CNVs) were called with
a sliding-window algorithm with a ten-probe minimum size
threshold,17 which allowed the detection of events greater than
40 kb. Candidate CNVswere deletions and duplications disrupting
two genes transcribed on the same strand. DNA from 168 addi-
tional control individuals was screened by exome sequencing.
Library construction, exome capture, and sequencing were carried
out as previously described.18 CNVs were derived with CoNIFER.19
It was previously determined that exome sequencing on our
laboratory platform is as sensitive as NimbleGen HD2 aCGH in
detecting CNVs that would be candidates for chimeric events.19
CNVs detected by either platform were defined as rare if no event
with greater than 60% overlap was present on the Database of
Genomic Variants20 at a frequency greater than 0.001, as previ-
ously described.1 Furthermore, candidate chimeric events were
screened against CNVs detected in 19,585 individuals (Cooper
et al., 2011,21 and data not shown), and events present at a fre-
quency 0.001 or greater were excluded. To determine genomic
breakpoints, we performed long-range PCR amplification on
genomic DNA with TaKaRa LA Taq as described in the manu-
facturer’s protocol. PCR products were Sanger sequenced with
breakpoint primers and additional sequencing primers as neces-
sary in order to reach breakpoints. All primer sequences are
included in Table S1 (available online).
Bioinformatic Analysis of Gene Expression
in Human Brain
For analysis of MATK and ZFR2 expression across developmental
time points in the human brain, we used RNA sequencing (RNA-
seq) data from the BrainSpan Atlas of the Developing Human698 The American Journal of Human Genetics 93, 697–710, OctoberBrain. Normalized gene expression levels for 26 different brain
tissues in ten different developmental periods were obtained
from the BrainSpan RNA-seq data set version 3. Tissue qualifi-
cation, processing and dissection, and experimental and bioinfor-
matics procedures are described in the technical white paper of
the data set. Normalized values of expression of parent genes
were obtained from 149 frontal cortex samples at different
developmental ages. Developmental ages were grouped into ten
developmental periods: early fetal (8–12 weeks gestation), early-
mid fetal (13–18 weeks gestation), late-mid fetal (19–24 weeks
gestation), late fetal (25–38 weeks gestation), early infancy
(birth–5 months), late infancy (6–18 months), early childhood
(19 months–5 years), late childhood (6–11 years), adolescence
(12–19 years), and adulthood (20–60þ years). Median expression
levels for each gene in each period were calculated and plotted.Transcript Analysis and Expression Constructs
First strand cDNA synthesis of subject lymphoblast cell line RNA
or of total RNA from different human tissues (Clontech Labora-
tories) was performed with SuperScript III (Life Technologies)
primed with random hexamers and/or gene-specific primers.
Chimeric transcripts were amplified with PCR primers targeted
to flanking exons and Sanger sequenced.
To generate expression constructs, we amplified MAP3K3,
DDX42, DNAJA2, MAP3K3-DDX42 transcripts 1 and 2, PLEKHD1-
SLC39A9 transcripts 1 and 2, and DNAJA2-NETO2 transcripts 1
and 2 from subject lymphoblast cDNA, PLEKHD1 and ZFR2 from
human brain cDNA (Clontech), SLC39A9 from a commercial
cDNA clone (Origene), andMATK fragment from subject genomic
DNA. MAP3K3-DDX42 and PLEKHD1-SLC39A9 chimeras and
parents were cloned into TOPO-TA pcDNA3.1 C-terminal V5- and
His-tagged mammalian expression vector (Life Technologies).
DNAJA2-NETO2 chimeras and parents were cloned into an
N-terminal V5-tagged pcDNA3 expression vector (a gift of Wendy
Roeb) with the Gateway system (Life Technologies). ZFR2
and MATK-ZFR2 constructs were assembled with the Gibson
method.22 All inserts were fully Sanger sequenced and free of
nonsynonymous PCR errors.Cell Culture and Transfections
Human embryonic kidney (HEK) 293 cells (ATCC) were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum and 1% penicillin and streptomycin.
Cortical neurons from P0 C57BL/6 mice were plated at a density
of ~25,000–50,000 per well onto a bed of confluent astrocytes
on poly-D-lysine- and collagen-treated coverslips. Neurons were
cultured in DMEM with B27 and 10% horse serum. Mitotic inhib-
itor (5 mM 5-fluoro-20-deoxyuridine and 12.5 mM uridine) was
added at 2 days in vitro (DIV). Experiments were performed
according to the guidelines for the care and use of animals
approved by the Institutional Animal Care and Use Committee
at the University of Washington. Cells were transfected with
Lipofectamine 2000 (Life Technologies) according to themanufac-
turer’s protocol. Cortical cells were cotransfected at 9 or 10 DIV
with GFP pCMV (0.6 mg) and experimental construct or empty
vector (2.4 mg). Media was changed after 4 hr, and transfections
proceeded for 24 hr.Western Blotting and Immunoprecipitation
HEK 293 cells were lysed in radio-immunoprecipitation assay
buffer (50 mM Tris-HCL [pH 7.4], 1% NP-40, 0.25% sodium3, 2013
deoxycholate, 150mMNaCl, and1mMEDTA)with completemini
protease inhibitor cocktail tablets (Roche) and Halt Protease and
Phosphatase Inhibitor Single-Use Cocktail (Thermo Fisher
Scientific) and quantitated with the Bradford method. Western
blotswere imagedwith anOdyssey Infrared Imager system (LI-COR
Biosciences). For analysis of MAPK activation, blots were probed
with phosphospecific antibodies and stripped and reprobed
with antibody to total JNK, p38, or actin. Primary antibodies used
were mouse anti-V5 (1:5,000, Life Technologies), rabbit anti-
b-actin (1:1,000, Santa Cruz Biotechnology), mouse anti-b-actin
(1:10,000, Sigma-Aldrich), rabbit anti-MEK5 (1:10,000, Abcam),
rabbit anti-phospho-MEK5 (1:500, SantaCruzBiotechnology), rab-
bit anti-p-ERK1/2 (1:1,000, Cell Signaling Technology), mouse
anti-phospho-JNK (1:500, Santa Cruz Biotechnology), rabbit anti-
phospho-p38 MAPK (1:1,000, Cell Signaling), rabbit anti-JNK
(1:1,000, Cell Signaling), and rabbit anti-p38a (1:500, Santa Cruz
Biotechnology). Experiments were performed in triplicate, and
paired two-tailed t tests were used for statistical analysis. For
immunoprecipitation, transfected HEK 293 cells were lysed with
NP-40 buffer (1% NP-40, 0.15 M NaCl, and 0.01 M Sodium
phosphate) with same protease and phosphatase inhibitors and
quantitated as above. Lysates were immunoprecipitated with
Protein G Dynabeads (Life Technologies) conjugated to mouse
anti-V5 (1:100, Life Technologies) according to the manufacturer’s
protocol. Two independent replicates were performed.Immunocytochemistry
HEK 293 cells or cultured neurons were fixed with 4% para-
formaldehyde for 20 min at room temperature. Cells were per-
meabilized with 0.5% Triton X-100 in PBS for 10 min at room
temperature and blocked in 5% normal goat serum (0.25% Triton
X-100 in PBS for 1 hr at 4C). Cultured cells were incubated over-
night at 4Cwithmouse monoclonal V5 primary antibody (1:200,
Life Technologies), rinsed four times in PBS, and incubated in
Alexa 568-conjugated goat secondary antibody (1:400, Life Tech-
nologies) for 1–2 hr at room temperature. Then, cells were washed
three times in PBS and mounted on slides with ProLong Gold
Antifade media containing DAPI (Life Technologies).Microscopy
Immunofluorescence images were acquired on a Zeiss 510 Meta
Confocal Microscope with 403 or 633 oil immersion objectives.
Gain and offset were adjusted for each image in order to optimize
dynamic range. For localization in HEK 293 cells, we measured the
fluorescence intensity of DAPI and transfected protein along a
30 mm line drawn through the center of each transfected cell in
a 403 image with Plot Profile function in ImageJ. Dendritic local-
ization was analyzed in images taken with a 633 objective and
33–43 zoom. Images were acquired in z series (0.4 mm steps),
rendered with maximum intensity projections, and analyzed in
ImageJ. Profiles of GFP and Alexa 568 fluorescence were made
with the Plot Profile function for a rectangular selection around
the longest straight segment of a dendrite. Branching sites were
indicated manually on the basis of GFP imaging of dendrites. To
correct for variation in background staining intensity and trans-
fection efficiency, we normalized fluorescence values, and mean
intensities at and between branching sites were calculated. To
correct for increased fluorescence at branch sites due to the
widening of dendrites, we divided normalized mean Alexa 568
fluorescence intensity by normalized mean GFP fluorescence in-
tensity. Data presented are from three independent experiments.The AmericResults
Discovery of Chimeric Genes
We screened DNA from 124 affected individuals with
schizophrenia with aCGH then scanned genome wide
for CNVs longer than 30 kb. CNVs in DNA of 290
matched controls were detected by either the same
aCGH platform (n ¼ 122) or exome sequencing (n ¼
168; CNVs derived with CoNIFER19). We eliminated
CNVs present in the Database of Genomic Variants.20
From the remaining events, we selected those predicted
to delete or duplicate both the 50 end of one gene and
the 30 end of another. Breakpoints of all candidate
chimeric events were obtained by PCR with diagnostic
primers followed by Sanger sequencing. To detect chi-
meras formed by inverted tandem duplications, we de-
signed breakpoint primers in order to test for an inverted
orientation when a duplication disrupted two genes on
opposite strands. This approach did not yield additional
putative chimeras.
Several filters were applied to each validated genomic
chimera: (1) the 50 parent gene was expressed in brain,
as determined by RT-PCR or by published report, (2) the
event had a frequency <0.001 in CNVs from 19,585
controls, and (3) the predicted protein product included
>5% of the protein coding sequence of at least one gene.
Four candidate chimeric events passed through all the
filters, all of which were in affected individuals (Figure 1).
These are fusions of Mitogen-activated protein kinase
kinase kinase 3 (MAP3K3 [MIM 602539]) to DEAD box
protein 42 (DDX42 [MIM 613369]; MAP3K3-DDX42),
DNAJ homolog subfamily A member 2 (DNAJA2 [MIM
611322]) to Neuropilin and tolloid-like 2 (NETO2 [MIM
607974]; DNAJA2-NETO2), Pleckstrin homology domain-
containing family D member 1 (PLEKHD1) to Solute
carrier family 39 member 9 (SLC39A9), and Megakaryo-
cyte-associated tyrosine kinase (MATK [MIM 600038]) to
Zinc finger RNA-binding protein 2 (ZFR2) (MATK-ZFR2).
In total, we detected four chimeric events meeting our
criteria in 124 affected individuals and zero in 290 control
individuals (p ¼ 0.002 by two-tailed Fisher’s exact test).
The characteristics of these candidate chimeric genes are
outlined in Table 1, and excluded events are described
in Table S2.Evaluation of Transcripts of Parent and Chimeric
Gene mRNA
Next, we obtained lymphoblast RNA from each individual
and designed primers in order to detect the predicted
chimeric mRNA. We detected MAP3K3-DDX42, DNAJA2-
NETO2, and PLEKHD1-SLC39A9 chimeric transcripts
(Figure 2A). MAP3K3-DDX42 had two stable transcripts.
MAP3K3-DDX42 transcript 2 is spliced at noncanonical
sites in the middle of exons, the donor site being located
in MAP3K3 exon 4 and the acceptor site in DDX42
exon 17. Both MAP3K3-DDX42 chimeras are in frame.an Journal of Human Genetics 93, 697–710, October 3, 2013 699
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Figure 1. CNVs Resulting in the Forma-
tion of Chimeric Genes in Individuals
with Schizophrenia
Deletion (red dashed lines) and dupli-
cations (blue dashed lines) result in the
formation of MAP3K3-DDX42, DNAJA2-
NETO2, PLEKHD1-SLC39A9, and MATK-
ZFR2 chimeric genes. For each event,
we indicate hg19 genomic coordinates,
impacted genes with direction of tran-
scription (50 parent genes are green, 30
parent genes are purple, and deleted genes
are black), regions targeted by PCR primers
for breakpoint validation (red arrows), his-
tograms of aCGH hybridization Z scores,
and resulting chimeric gene.Two DNAJA2-NETO2 transcripts resulted from alternate
splicing of NETO2 exon 8. Both are out of frame, adding
11 (transcript 1) or 8 (transcript 2) frame-shifted codons
before a premature stop. PLEKHD1-SLC39A9 also had two
transcripts, resulting from the inclusion of alternate 30
UTRs of SLC39A9.
The chimeric MATK-ZFR2 transcript could not be
amplified from lymphoblasts of the duplication carrier,
consistent with the expression profiles of the two parent
genes, both of which were expressed only in the
adult and fetal brain (Figure 2B). Evaluation of the parent
gene ZFR2 revealed a second transcript characterized
by the deletion of ZFR2 exon 15 (95 base pairs) and, there-
fore, an altered reading frame. Both ZFR2 transcripts700 The American Journal of Human Genetics 93, 697–710, October 3, 2013were consistently detected in all
brain regions (Figure 2C) and, there-
fore, may be included in brain-ex-
pressed MATK-ZFR2 chimeras.
Functional Evaluation of Fusion
Proteins
All four chimeric genes produced
stable proteins when transiently ex-
pressed in mammalian cells.
MAP3K3-DDX42
The MAP3K3-DDX42 chimera is the
only chimera resulting from a dele-
tion, so the individual’s genome in-
cludes only a single functional copy
of each parent gene. Furthermore,
the 150 kb event fully deletes three
interstitial genes (LIMD2, STRADA
[MIM 608626], and CCDC47), one
of which—STRADA—is known to
regulate dendritic and axonal out-
growth.23 In addition, the MAP3K3-
DDX42 chimera contains substantial
coding sequence from both con-
stituent genes; therefore, the fusion
protein could impact two different
pathways. For the present study,we focused on the function of fusion proteins in the
well-known ERK5 pathway (encoded by MAPK7 [MIM
602521), which includes the 50 gene, MAP3K3.24
The two MAP3K3-DDX42 fusion proteins were 75.1
and 12.9 kD (Figures 3A and 3B). In transfected HEK 293
cells, localizations of both fusion isoforms differed from
those of their parent proteins (Figure 3C). MAP3K3 was
predominantly cytoplasmic, and DDX42 was pre-
dominantly nuclear, consistent with previously reported
localizations.25; 26 In contrast, the localization of trans-
fected MAP3K3-DDX42 isoforms 1 and 2 was highly
variable: preferentially or exclusively in the nucleus in
some cells, in the cytoplasm in others, and, in still
others, diffused equally throughout the cell (Figure 3D).
Table 1. Chimeric Genes in Persons with Schizophrenia
Case ID
CNV
Coordinates
(hg19)
Gain/
Loss
CNV
Size (kb)
50 GENE
(size in aa)
30 GENE
(size in aa)
Same
frameb
Length of
predicted
fusion proteinsc
Brain Expressiond
Freq.e
Age at
onset50 gene 30 gene
SZ113 chr17:61737993-
61887860a
Loss 150 MAP3K3 (657) DDX42 (938) Y 128 þ 554 Y Y 0 16
SZ61 Chr16:47004235-
47124878
Gain 121 DNAJA2 (412) NETO2 (525) N 120 þ 11 Y Y 0 26
SJW19 chr14:69921835-
69979453
Gain 57.6 PLEKHD1 (506) SLC39A9 (307) Y 186 þ 121 Y Y 0.00075 16
SZ25 Chr19:3800538-
3847280
Gain 46.7 MATK (508) ZFR2 (939) Y 0 (50-UTR) þ 839 Y Y 0.00072 20
The following abbreviations are used: CNV, copy-number variant; kb, kilobases; aa, amino acids.
aMAP3K3-DDX42 breakpoints sequenced to nearby alu.
bIndicates whether the second gene is predicted to be in the same frame as the first one when fused.
cAmino acids contributed by 50 gene and amino acids contributed by 30 gene.
dDetermined by RT-PCR of human brain cDNA.
eFrequency of CNV in 19,585 control individuals.We observed a similar pattern in transfected mouse cortical
neurons (Figure S1).
The canonical role of MAP3K3 is the activation of
mitogen-activated protein kinase ERK5.24 In response to
extracellular signals, MAP3K3 and its downstream kinase
MEK5, encoded by MAP2K5 (MIM 602520), are activated
by heterodimerization and phosphorylation and, in turn,
phosphorylate ERK5.27; 28 MAP3K3-MEK5 dimerization
occurs at N-terminal PB1 (Phox Bem 1p) domains29 pre-
sent in both proteins, whereas phosphorylation is medi-
ated by C-terminal kinase domains.24 The expression of
a truncated MAP3K3 PB1 domain or a kinase-dead
MAP3K3 results in the dominant-negative inhibition of
ERK5 activation.27,29 Similar to these engineered domi-
nant-negative proteins, MAP3K3-DDX42 isoform 1 in-
cludes an intact PB1 domain but has the DDX42 helicase
domain in place of the kinase domain (Figure 3A). We
examined whether this fusion protein binds to MEK5.
Immunoprecipitation of transfected HEK 293 cells indi-
cated that MAP3K3 and MAP3K3-DDX42 isoform 1 bind
endogenous phosphorylated MEK5, whereas DDX42 and
MAP3K3-DDX42 isoform 2 do not (Figure 4A). This sug-
gests that MAP3K3-DDX42 isoform 1 likely acts as a domi-
nant-negative inhibitor of ERK5 signaling.
MAP3K3 also has a noncanonical role in the activation
of three other MAPK cascades: p38 (encoded by MAPK14
[MIM 600289]),30 JNK (encoded by MAPK8 [MIM
601158]),30 and ERK1 and ERK2 (encoded by MAPK1
[MIM 176948] andMAPK3 [MIM 601795].31 MAP3K3 acti-
vity in these pathways is not thought to involve hetero-
dimerization at the PB1 domain.29 We compared the
activation of each of these pathways in cells transfected
with MAP3K3 orMAP3K3-DDX42 chimeras alone or those
cotransfected with MAP3K3 and the MAP3K3-DDX42
chimeras (Figures 4B and 4C). MAP3K3 activated ERK1
(p ¼ 0.006), ERK2 (p ¼ 0.009), and p38 (p ¼ 0.011), but
MAP3K3-DDX42 fusions did not, as predicted by the
lack of a kinase domain in fusion proteins. Our data alsoThe Americsuggest that both fusions may slightly suppress the activa-
tion of ERK1 and p38 (but it was not statistically signifi-
cant). JNK was not activated by MAP3K3 or the fusion
proteins, but there was evidence that JNK activation was
suppressed by the fusion proteins (but it was not statisti-
cally significant).
DNAJA2-NETO2
DNAJA2-NETO2 fusion protein isoforms 1 and 2 were 14.7
and 14.3 kD (Figures 5A and 5B). The parent protein
DNAJA2 is 45.7 kD. Protein levels of isoform 1 were lower
than protein levels of isoform 2 and full-length DNAJA2,
suggesting nonsense-mediated decay of DNAJA2-
NETO2 transcript variant 1 as its premature termination
codon arises more than 100 nucleotides 50 of the nearest
exon boundary.32 Furthermore, DNAJA2-NETO2 localiza-
tion was altered in HEK 293 cells. The parent protein
DNAJA2 was excluded from the nucleus, as previously
reported,33 whereas the fusion proteins were localized
throughout the nucleus and cytoplasm (Figures 5C
and 5D).
PLEKHD1-SLC39A9
PLEKHD1-SLC39A9 fusion protein isoforms 1 and 2
are 34.0 and 26.4 kD (Figures 6A and 6B). PLEKHD1 is
59.2 kD. SLC39A9 is predicted to have a molecular weight
of 32.4 kD but appears much smaller according to western
blot (~15 kD), suggesting that the protein product may be
cleaved.
MATK-ZFR2
ZFR2 contributes the entire coding sequence of the
MATK-ZFR2 fusion protein. Little is known about ZFR2.
We detected two ZFR2 transcript variants in the human
brain and predicted MATK-ZFR2 chimeras for both vari-
ants. ZFR2 transcript variant 2 is characterized by the
omission of exon 15, which leads to a shift of the reading
frame. This frameshift does not result in premature trunca-
tion but, instead, codes for a 946aa protein that differs
from the 938aa ZFR2 isoform 1 in its C-terminal 198
residues (Figure S2). We generated expression constructsan Journal of Human Genetics 93, 697–710, October 3, 2013 701
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Figure 2. Characterization of Chimeric
Transcripts
(A)MAP3K3-DDX42, DNAJA2-NETO2, and
PLEKHD1-SLC39A9 chimeric transcripts
were detected by RT-PCR of RNA from
lymphoblast cell lines (LCLs). Sanger
sequence traces show chimeric junctions.
MATK-ZFR2 chimeric transcripts were not
detected in lymphoblasts. Red arrows
indicate exons targeted by forward and
reverse primers. The expression of each 50
parent gene, tested by RT-PCR, is indicated
for human brain and LCLs.
(B) Parent genes MATK (M) and ZFR2 (Z)
were expressed only in brain and fetal
brain, as determined by RT-PCR of cDNA
from indicated tissues. Tissue legend: Brn,
adult brain; F Br, fetal brain; Liv, liver;
Hea, heart; Ske, skeletal muscle; Pan,
pancreas; Pla, placenta; Kid, kidney; Lym,
lymphoblasts; and DNA, genomic DNA
(negative control).
(C) MATK and ZFR2 were expressed in
every brain region tested, and two ZFR2
transcripts were present, distinguished by
the alternate splicing of exon 15. Tissue
legend: Brn, adult brain; F Br, fetal brain;
CC, cerebral cortex; Cer, cerebellum; Put,
putamen; Hip, hippocampus; FL, frontal
lobe; and TL, temporal lobe.for both ZFR2 transcripts and their respective chimeras
with MATK (Figure 7A). The chimeras include a 50 UTR
of MATK and all but the first exon of ZFR2, and as a
result, lack the wild-type start codon. Observed molecular
weights of the fusion proteins (predicted to be 97.3 and
97.8 kD) (Figure 7B) were consistent with translation
initiation occurring at the first Methionine codon in
ZFR2 exon 2, Met41, which is in the correct reading frame
and has a strong Kozak sequence (GGGATGG).34
One potential pathogenic mechanism of the MATK-
ZFR2 chimera could be the altered expression of ZFR2
as a result of fusion to promoter sequences upstream of
or within the 50 UTR of MATK. We compared temporal
expression patterns of MATK and ZFR2 with RNA-seq
data from human prefrontal cortex from the BrainSpan
Atlas of the Developing Human Brain (Figure 7C).
MATK is upregulated between the late fetal period and
early infancy, whereas ZFR2 expression remains at a
relatively constant low level. We also compared the
expression patterns of parent genes across brain subre-
gions and in whole adult and fetal brain with publicly
available gene expression data from 128 human tissues
curated from 1,068 published microarray experiments35
(Figure S3). MATK and ZFR2 differ in expression most
dramatically in a subset of brain structures, including
the cingulate cortex, pons, caudate nucleus, and globus
pallidus. Fusion of MATK and its upstream regulatory
elements to most of the coding sequence of ZFR2 may
lead to the aberrant overexpression of ZFR2 isoforms 1
and 2 at critical developmental times and in specific
brain regions.702 The American Journal of Human Genetics 93, 697–710, OctoberBecause MATK and ZFR2 are expressed only in the
brain, we evaluated localization in transfected mouse
cortical neurons. The localization of MATK-ZFR2 fusion
proteins did not appear to differ from their full-length
ZFR2 counterparts, but the two isoforms of ZFR2 had
distinct localization patterns. ZFR2 isoform 1 and MATK-
ZFR2 isoform 1 were predominantly in the nucleus but
were also diffusely expressed in the cell soma and pro-
cesses (Figures 8A and 8B). In contrast, ZFR2 isoform 2
and MATK-ZFR2 isoform 2 were largely excluded from
the nucleus with a granular staining pattern (Figures 8C
and 8D). Within the dendrites, we found that ZFR2 iso-
form 2 and its chimera localized preferentially to branch
sites (Figures 8E and 8F). Nuclear localization of ZFR2 iso-
form 1 may be driven by a putative nuclear localization
signal at amino acids 913–93336 (Figure 7A) within the
C-terminal region absent from ZFR2 isoform 2, potentially
accounting for the difference in localization between the
two isoforms.Discussion
We found an increased burden of rare, brain-expressed
chimeric genes in individuals with schizophrenia, and
there were four events in 124 affected individuals com-
pared to zero events in 290 control individuals. Because
each event arises in only a single affected individual
in our series, we cannot establish causality for any one
chimera. However, the results support the theory that
rare chimeric genes as a group contribute to schizophrenia3, 2013
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Figure 3. Synthesis and Altered Locali-
zation of MAP3K3-DDX42 Fusion Proteins
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(arrows).
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p values show chi-square comparisons of
distributions.and are consistent with multiple lines of evidence suggest-
ing that mutations leading to chimeric genes are likely to
be deleterious.
MAP3K3-DDX42
Our results suggest thatMAP3K3-DDX42 is likely to act as a
dominant-negative inhibitor of ERK5 signaling by binding
to activated MEK5. The ERK5 signaling cascade is critically
important in neuronal differentiation and proliferation,
neuroprotection, and adult neurogenesis37–39 and may
be misregulated in neuropsychiatric illnesses including
autism and major depressive disorder (MIM 608516).40,41
Our findings also suggest that MAP3K3-DDX42 may have
slight inhibitory effects on JNK, p38, and ERK1 signaling,
all of which function in brain processes, including synap-
tic plasticity and inflammation.42–44 These effects may be
more pronounced against a genetic background haploid
at this locus, as in this affected individual.
DDX42, the 30 parent of MAP3K3-DDX42, codes for
a brain-expressed RNA helicase thought to mediate
response to viral infection of the CNS.45 Recently,
DDX42 was shown to modulate the effect of the proapo-
ptotic protein ASPP2, which is encoded by TP53BP2 (MIM
602143).26 DDX42 interferes with the induction of
apoptosis by ASPP2 and excludes ASPP2 from the nucleus.
Intriguingly, a brain-specific function for ASPP2 has
recently emerged: the control of polarity and proliferation
of neural progenitor cells during CNS development.46
ASPP2 targeting to the apical junctional complex in
these neural progenitors is thought to be critical for
these functions.46 MAP3K3-DDX42 isoform 1 includes
the DDX42 residues that bind ASPP2, but the protein isThe Americmislocalized. DDX42 is predominantly nuclear, whereas
the subcellular localization of fusion isoform 1 is highly
variable. Aberrant cytoplasmic localization of the fusion
protein, including the C terminus of DDX42, may allow
it to access ASPP2 at the apical junctional complexes,
potentially interfering with its critical role in neural pro-
genitor proliferation.
DNAJA2-NETO2
DNAJA2-NETO2 is an out-of-frame chimera, and as such
NETO2 does not contribute any protein-coding sequence
to the fusion protein. Nonetheless, the contribution of a
naturally occurring 30 end to the mRNA may improve
the ability of RNA processing machinery to recognize
and maintain this aberrant mRNA in comparison to
genomic deletions or duplications that result in a
simple truncation. 30 UTRs have been shown to have
profound, sequence-dependent regulatory effects on
their respective genes via microRNA binding, polyadeny-
lation, translational control, and mRNA localization
(for review, see Jia et al., 201347). NETO2 is involved in
glutamate signaling in the brain,48 and its 30 end should
stabilize rather than destabilize the chimeric mRNA in
brain tissue.
DNAJA2 is a brain-expressed member of the J protein
family, which consists of cochaperones of heat shock pro-
tein 70 (HSP70) proteins.33 DNAJA2 promotes degradation
of the cardiac hERG potassium channel49 and enhances
the HSP70-mediated refolding of neural G proteins.50
These roles are likely mediated by two distinct but inter-
related functions of DNAJA proteins. First, they activate
folding by HSP70 via ATP hydrolysis.51 Second, theyan Journal of Human Genetics 93, 697–710, October 3, 2013 703
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(A) HEK 293 cells were transfected with empty vector (VEC),
MAP3K3-DDX42 parent genes (MAP and DDX), or chimeras
(MD1 and MD2), and lysates were immunoprecipitated with a
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phospho-MEK5 and show binding of phospho-MEK5 by
MAP3K3 and MAP3K3-DDX42 isoform 1.
(B) We evaluated the activation of MAPK pathways in HEK 293
cells transfected with the indicated combinations of MAP3K3
andMAP3K3-DDX42 constructs with phospho-specific antibodies
against ERK1 and ERK2, p38, and JNK. Representative blots and
optical density (OD) of each band normalized to an appropriate
loading control are shown.
(C) Mean normalized densitometry values from three replicate
experiments are shown for ERK1, ERK2, p38, and JNK. Equivalent
amounts of each construct were transfected for all conditions,
and the total amount of transfected DNA was kept constant
by the addition of empty vector as necessary. Error bars repre-
sent SEM.homodimerize, forming a clamp-like structure that binds
target proteins for delivery to HSP70.52 The first func-
tion is shared by all J proteins and is mediated by the
N-terminal J domain. The latter function is more specific
to DNAJA proteins and is mediated by central and
C-terminal domains.
DNAJA2-NETO2 fusion proteins include only the J
domain. Similar mutations in other J domain family pro-704 The American Journal of Human Genetics 93, 697–710, Octoberteins have been studied. One pertinent study found that
the expression of an isolated J domain in mammalian cells
completely blocks luciferase refolding by endogenous
HSP70 and impairs cell growth.53 This dominant-negative
effect is thought to result from inefficient ATPase activ-
ity of the isolated J domain, which, therefore, prevents
binding and activation by full-length J proteins and other
chaperones. DNAJA2-NETO2 fusion proteins may have an
analogous dominant-negative function, preventing the
proper folding of key substrates. Furthermore, the observed
mislocalization of DNAJA2-NETO2 proteins to the cyto-
plasm may contribute to a deleterious effect via a gain-of-
function mechanism.
PLEKHD1-SLC39A9
Both parent genes of the PLEKHD1-SLC39A9 chimera are
broadly expressed, including in the fetal and adult brain,
but their role in the CNS has not been studied. PLEKHD1
is an uncharacterized gene that has an N-terminal Pleck-
strin homology (PH) domain. PH domains exist in a wide
range of proteins and are generally involved in intracel-
lular signaling by binding to phosphatidylinositol lipids
and recruitment of target proteins to the cell mem-
brane.54 SLC39A9 codes for the zinc transporter ZIP9,
which was recently shown to enhance AKT1 (encoded by
AKT1 [MIM 164730]) and ERK1 and ERK2 phosphory-
lation in immune cells by regulating intracellular zinc con-
centration.55 Signaling through AKT1, ERK1, and ERK2 is
critical in the brain. As mentioned above, ERK1 and
ERK2 are also activated by MAP3K3 as well as DISC1,56
and are involved in processes including neuroprotec-
tion39 and synaptic plasticity.44 AKT1 is a protein kinase
central to multiple signaling cascades in the brain and
has been identified as a point of convergence of many
known schizophrenia risk factors.56,57 The fusion proteins
contain both the PH domain of PLEKHD1 and the zinc
transporter domain of ZIP9 and potentially interfere with
functions of both genes.
MATK-ZFR2
ZFR2 is a previously uncharacterized gene that is similar
by sequence homology and predicted protein structure to
ZFR, a member of the double-stranded RNA-binding
family.58 ZFR mediates nucleocytoplasmic shuttling and
the transport of ribonuclear particles into neurites.59 ZFR
binds the brain-expressed RNA-binding protein STAU2
(MIM 605920), and ZFR2 likely has a different binding
partner. C. elegans have a single gene, Y95B8A.7, ortholo-
gous to ZFR and ZFR2, which, when targeted by RNAi,
leads to defects in axon guidance.60
The localization of ZFR2 isoform 1 is similar to that of
ZFR in neuronal cells, which is present at high levels in
the nucleus and lower levels in the cytoplasm. By contrast,
ZFR2 isoform 2 is excluded from the nucleus and shows
preferential localization to dendritic branch sites. This
staining pattern is similar to that of other neuronal RNA-
binding proteins, such as Staufen and FMRP in Drosophila3, 2013
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Figure 5. Synthesis and Altered Localiza-
tion of DNAJA2-NETO2 Fusion Proteins
(A) Expression constructs for DNAJA2-
NETO2 chimeras and full-length DNAJA2
were transfected into HEK 293 cells.
Known functional domains and place-
ment of V5 epitope tag are indicated. The
figure is not to scale.
(B) Western blot shows protein levels for
transfected genes and loading control.
DN1 and DN2 are DNAJA2-NETO2 iso-
forms 1 and 2. Molecular weights of pro-
tein ladder are indicated in kD.
(C) Representative micrographs of trans-
fected cells show the nuclear exclusion of
DNAJA2 in comparison to the increased
nuclear localization of both DNAJA2-
NETO2 chimeras. Average fluorescence in-
tensity of DAPI and V5 stain are shown
along a 30 mm line drawn centered on
the nucleus in the indicated number of
cells for each transfection condition. Re-
sults are from three independent experi-
ments. Error bars show SEM.neurons,61 and zipcode-binding protein 1 (ZBP1), which
regulates the formation of dendritic arbors in rat hippo-
campal neurons.62 Intriguingly, both knockdown and
the overexpression of ZBP1 have been shown to impair
dendritic arborization.62 We postulate that ZFR2 isoforms
1 and 2 have distinct functions within the neuronal
RNA binding pathway. On the basis of evidence from
subcellular localization, isoform 1 may be involved in
the nucleocytoplasmic shuttling of ribonucleoparticles,
whereas isoform 2 may regulate dendritic branching by
transporting specific ribonucleoparticles into neuronal
processes. The fusion of ZFR2 to the 50 UTR and putative
regulatory regions of MATK is predicted to result in
overexpression of both isoforms of ZFR2 in the brain at
critical developmental time points, potentially disrupting
these functions and leading to aberrant dendritic arboriza-
tion. Additional functional work is necessary in order to
evaluate the functions of these proteins and determine
the likely outcome of overexpression.PLEKHD1
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Features of Chimerism
Chimerism is an important mutational mechanism
that potentially impacts evolution and disease. NewlyV5
EK SLC PS2 PS1 Figure 6. Stable Synthesis of PLEKHD1-
SLC39A9 Fusion Proteins
(A) Expression constructs for PLEKHD1-
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transfected genes and loading control.
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and PS2 are PLEKHD1-SLC39A9 isoforms
1 and 2. Molecular weights of protein
ladder are indicated in kD.
an Journal of Human Genetics 93, 697–710, October 3, 2013 705
ZFR2
Isoform 1
MATK-ZFR2
Isoform 2
ZFR2 
Isoform 2
MATK-ZFR2
Isoform 1
actin
V5
ZFR2
Iso.1
M-Z
Iso.1
ZFR2
Iso.2
M-Z
Iso.2
DZF domain
748 946650270-
300
470-
500
320-
350
V5
1
V5
DZF domain
708 906610230-
260
430-
460
280-
310
DZF domainZinc finger domains
Zinc finger domains
Zinc finger domains
Zinc finger domains
900 938650270-
300
470-
500
320-
350
V5
V5
1
DZF domain
860 898610230-
260
430-
460
280-
310
75
100
150
50
37
A
B C
0
10
20
30
40
50
60
E
ar
ly
Fe
ta
l
E
ar
ly
-m
id
fe
ta
l
La
te
-m
id
fe
ta
l
La
te
fe
ta
l
E
ar
ly
in
fa
nc
y
La
te
in
fa
nc
y
E
ar
ly
ch
ild
ho
od
La
te
ch
ild
ho
od
A
do
le
sc
en
ce
A
du
lth
oo
d
MATK
ZFR2
Developmental Stage 
m
ea
n 
ex
pr
es
si
on
 in
 h
um
an
 fr
on
ta
l c
or
te
x
Figure 7. Synthesis of MATK-ZFR2
Fusion Proteins and Developmental
Regulation of Parent Genes
(A) Expression constructs for two isoforms
of parent gene ZFR2 and respectiveMATK-
ZFR2 chimeras were transfected into HEK
293 cells. Known functional domains
and placement of V5 epitope tag are indi-
cated. Yellow bars are putative nuclear
localization signals, and black diagonal
lines indicate the region altered by exon
skipping and frameshift. The figure is not
to scale.
(B) Western blot shows protein levels for
transfected genes and loading control.
Molecular weights of protein ladder are
indicated in kD.
(C) Normalized expression values for
MATK and ZFR2 in the human prefrontal
cortex plotted at different developmental
ages. Data were obtained from the Allen
Brain Atlas BrainSpan RNA-seq data set
and represent 149 human frontal cortex
samples.emerging chimeric genes have the potential to create pro-
teins with new functions. For example, a recent study
compared the phenotypic impacts of different classes
of engineered mutations in the eleven genes of the
yeast mating pathway.64 The recombination of func-
tional domains into chimeric genes led to a striking
diversification in mating response, whereas whole-gene
duplications, single-domain duplications, and the coex-
pression of distinct functional domains did not. This
pattern is also evident in our results. The recombination
of functional domains in the MAP3K3-DDX42 or
PLEKHD1-SLC39A9 chimeras produces proteins with fea-
tures of both parents and the potential to interact with
multiple pathways. Such proteins could not result from
simple truncation, deletion, or duplication of parent
genes.
Even when a chimera includes protein-coding sequence
from only one gene, the recombination of regulatory
regions may also result in functional changes. A survey
of 14 conserved chimeric genes in Drosophila melanogaster
revealed dramatic regulatory differences between parent
genes and chimeras at the level of both subcellular locali-
zation and tissue-specific expression.65 We also observed
striking differences in regulatory patterns between parent
genes MATK and ZFR2, and both DNAJA2-NETO2 and706 The American Journal of Human Genetics 93, 697–710, October 3, 2013MAP3K3-DDX42 fusions had altered
subcellular localization. Altered local-
ization potentially influences the
mechanism of pathogenesis. When
present in the same cellular compart-
ment as a parent gene, the fusion
protein can carry out predicted
dominant-negative functions, such
as the inhibition of MAPK pathway
signaling by MAP3K3-DDX42 fu-sions. When present in different locations relative to
parent proteins, the same chimera may have potential
gain-of-function effects, such as aberrantly binding to
ASPP2.
Evidence for Causality
For private or very rare mutations, evidence of causality
is best obtained by functional studies demonstrating
biological relevance of the gene and biological conse-
quences of the mutation. For the chimeric genes in our
case series, the differences in localization, regulation,
or function between parent and fusion genes support
roles for these events in schizophrenia. Many of the
parent genes play important roles in the brain, including,
potentially, the gene ZFR2, for which we provide evi-
dence for a recently evolved role in dendritic branch-
ing. The neurodevelopmental pathways within which
these genes operate have been previously implicated in
schizophrenia, including neural precursor proliferation,
neuronal migration and integration, glutamate signaling,
and neurite outgrowth (for review, see Brandon and Sawa,
201166).
Our results also provide additional evidence that schizo-
phrenia is characterized by vast genetic heterogeneity. In
our cohort, only four cases are potentially explained by
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and 2 and MATK-ZFR2 Fusion Proteins
(A–D) Representativemicrographs of trans-
fected mouse cultured cortical neurons
show diffuse localization of ZFR2 isoform
1 (A) and MATK-ZFR2 isoform 1 (B)
throughout the nucleus and cytoplasm,
and bright puncta in the nucleus not colo-
calized with nucleoli. ZFR2 isoform 2 (C)
and MATK-ZFR2 isoform 2 (D) are largely
excluded from the nucleus and show a
granular staining pattern with many gran-
ules present at branch sites (triangles).
(E) Representative micrographs of single
dendrites and corresponding fluorescence
profiles from mouse cortical cells trans-
fected with ZFR2 isoform 2 or MATK-
ZFR2 isoform 2. Dendritic morphology
was visualized by cotransfected GFP. Hori-
zontal gray bars indicate manually anno-
tated branch sites.
(F) Mean fluorescence intensity (FI) of V5
in the dendritic trunk versus dendritic
branch sites normalized to GFP FI in order
to correct for increased dendrite diameter
at branch sites. Data are from three inde-
pendent replicates. p values represent sig-
nificance by two-tailed t test. Error bars
represent SEM.chimeras. Each fusion gene is rare, perhaps even unique to
one affected individual. Furthermore, each chimera differs
dramatically in regards to the architecture of the fusion,
the functions of the genes involved, and the predicted
mode of action, including the disruption of regulation
and localization.
In the modern era of gene discovery, it is now
possible to solve one case at a time. The disruption of
a gene important to neurodevelopment, by any number
of different mutational mechanisms (including chime-
rism), may contribute to neuropsychiatric disease. Given
that the majority of human genes are expressed in the
brain, and because each gene may be disrupted by a
number of different mutations, the number of potential
genetic causes of schizophrenia is vast. Although any
given damaging mutation impacting a gene or genes
likely explains only a small number of cases, the sum
total of individually rare severe events disrupting
brain development may explain a substantial portion
of illness.
The enrichment of rare brain-expressed chimeras in
persons with schizophrenia, and the analyses suggestingThe American Journal of Human Ga functional impact of these fusion
genes, support the theory that
chimeric genes play a role in the
illness, at least in a small number of
affected individuals. Exome and
whole-genome sequencing data in
large case series can be readily ex-
ploited in order to detect chimericgenes resulting from CNVs as well as inversions and
translocations. Future studies will reveal more about the
overall contribution of this class of mutation to schizo-
phrenia and other neuropsychiatric illnesses.Supplemental Data
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